Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

9.970 -0.300 (-2.92%)
Streaming Delayed Price Updated: 3:04 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish
BioCryst Pharmaceuticals raised its 2025 revenue and expense forecasts, projecting net income and positive cash flow for the year. 
Via Stocktwits
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow. 
Via Benzinga
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
Via Benzinga
Exposures Fossil Fuels
These stocks are gapping in today's session
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Earnings Scheduled For May 5, 2025
Via Benzinga
A Preview Of BioCryst Pharma's Earnings
Via Benzinga
Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased
BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
Via The Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings
BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025. 
Via Benzinga
Earnings Scheduled For February 24, 2025
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
7 Small-Cap Stocks to Buy for Large-Scale Gains
Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling. 
Via InvestorPlace
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally. 
Via The Motley Fool
BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic... 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
BCRX Stock Earnings: BioCryst Pharma Beats EPS, Beats Revenue for Q1 2024
BCRX stock results show that BioCryst Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
These penny stocks offer triple digit returns to investors right now but not many investors are aware of them. 
Via InvestorPlace
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
What's Going On With BioCryst Stock After Earnings?
BioCryst reported quarterly losses of 28 cents per share, missing the analyst consensus estimate of losses of 24 cents by 16.67% and representing a 26.32% increase over losses of 38 cents per share... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.